AstraZeneca has outlined ambitious goals for the end of the decade, aiming not only for “industry-leading growth” by 2030 but also securing a spot in at least the top three positions in its five focus areas. These areas include oncology, rare diseases, vaccines and immunotherapies, respiratory and immunology, as well as cardiovascular, renal, and metabolism. The company’s chief financial officer, Aradhana Sarin, emphasized that AstraZeneca’s wide geographic reach and extensive pipeline contribute to a “relatively de-risked” revenue growth compared to peers.
In the short term, AstraZeneca is targeting double-digit growth from 2021 to 2025, a goal that the company states it is “very much on track” to achieve. The confidence in these growth ambitions is bolstered by the company’s existing product portfolio, new indications, and a plan to launch 15 medications by 2030.
Novavax is reportedly in discussions with Walgreens to include its COVID-19 vaccine in the pharmacy’s stores for the 2024-25 season. While Walgreens opted not to carry the vaccine for the current season, Novavax anticipates a change, particularly as it expects FDA approval for its vaccine by the end of August or early September. The company is in the latter part of its first full COVID vaccination season in the U.S. and is planning further developments, including a COVID-flu combination vaccine slated for a phase 3 trial this year. AstraZeneca has outlined
Novavax CEO John Jacobs highlighted the company’s financial strength, with $2 billion in cash, emphasizing the potential to independently develop its COVID-flu combination vaccine. The company underwent significant cost-cutting measures in the past year, including “focused headcount reductions.” Meanwhile, Eli Lilly CEO David Ricks acknowledged Novo Nordisk’s pursuit of GLP-1s for obesity during a presentation and highlighted competition as a driving force for advancements in the field, envisioning the obesity market expanding beyond a “fixed pie.”
After more than 25 years in the field, Novo Nordisk has largely proved its obesity thesis, CEO Lars Fruergaard Jørgensensaid Tuesday at theJ.P. Morgan Healthcare Conference. But even as the potentially multi-billion-dollar market opens up, “we are just getting going,” the CEO said. Not long after Wegovy’s obesity launch, demand outstripped supply, with that inventory uncertainty persisting through 2023. As for the coming year, “I’m very comfortable looking into 2024—and specifically for Wegovy in the U.S.—that we can add significant additional volumes,” Jørgensen explained. That additional capacity for 2024 didn’t come all at once, either, the CEO pointed out. “This is a continued journey of building capacity for the years to come,” Jørgensen said.